Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase III study of paricalcitol vs maxacalcitol in Japanese hemodialysis patients with secondary hyperparathyroidism
jRCT2080221462Phase 3
- Sponsor
- Abbott Laboratories
- Start
- May 2011
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised trial of paricalcitol in secondary hyperparathyroidism (SHPT), chronic kidney disease (CKD) and end-stage kidney disease (ESKD) (2 arms), sponsored by Abbott Laboratories.
02
Drugs
paricalcitol
03
Conditions
secondary hyperparathyroidism (SHPT)chronic kidney disease (CKD)end-stage kidney disease (ESKD)
Beyond the preview
Go deeper on jRCT2080221462.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080221462.